- Home
- TGS vs BLCO Comparison
TGS vs BLCO Comparison
Compare TGS & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGS
- BLCO
- Stock Information
- Founded
- TGS 1992
- BLCO 1853
- Country
- TGS Argentina
- BLCO Canada
- Employees
- TGS N/A
- BLCO N/A
- Industry
- TGS Natural Gas Distribution
- BLCO Ophthalmic Goods
- Sector
- TGS Utilities
- BLCO Health Care
- Exchange
- TGS Nasdaq
- BLCO Nasdaq
- Market Cap
- TGS 4.4B
- BLCO 4.9B
- IPO Year
- TGS N/A
- BLCO 2022
- Fundamental
- Price
- TGS $22.07
- BLCO $15.14
- Analyst Decision
- TGS Strong Buy
- BLCO Hold
- Analyst Count
- TGS 1
- BLCO 11
- Target Price
- TGS $40.00
- BLCO $15.80
- AVG Volume (30 Days)
- TGS 663.0K
- BLCO 514.8K
- Earning Date
- TGS 11-03-2025
- BLCO 10-29-2025
- Dividend Yield
- TGS 4.20%
- BLCO N/A
- EPS Growth
- TGS 69.56
- BLCO N/A
- EPS
- TGS 0.35
- BLCO N/A
- Revenue
- TGS $1,027,524,722.00
- BLCO $4,891,000,000.00
- Revenue This Year
- TGS N/A
- BLCO $8.27
- Revenue Next Year
- TGS N/A
- BLCO $5.73
- P/E Ratio
- TGS $12.86
- BLCO N/A
- Revenue Growth
- TGS 2.37
- BLCO 8.81
- 52 Week Low
- TGS $18.15
- BLCO $10.45
- 52 Week High
- TGS $34.37
- BLCO $21.69
- Technical
- Relative Strength Index (RSI)
- TGS 37.64
- BLCO 57.06
- Support Level
- TGS $21.01
- BLCO $14.89
- Resistance Level
- TGS $24.01
- BLCO $15.50
- Average True Range (ATR)
- TGS 1.30
- BLCO 0.38
- MACD
- TGS -0.35
- BLCO -0.02
- Stochastic Oscillator
- TGS 20.53
- BLCO 64.14
About TGS Transportadora de Gas del Sur SA TGS
Transportadora de Gas del Sur SA is a transporters of natural gas in Latin America. The company's operating segments include Natural Gas Transportation, Midstream, Telecommunications, Production and Commercialization Liquids, Other Services, and Telecommunications. It generates maximum revenue from the Production and Commercialization of the Liquids segment. Geographically, it derives the majority of its revenue from Argentina.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.